SAN DIEGO, Calif. (AP) — Biotech giant Illumina says it will undo its $7.1 billion purchase of the cancer-screening company Grail after losing legal battles with antitrust enforcers in the U.S. and Europe. San Diego-based Illumina said in a Sun
SAN DIEGO, Calif. (AP) -- Biotech giant Illumina says it will undo its $7.1 billion purchase of the cancer-screening company Grail after losing legal battles with antitrust enforcers in the U.S. and Europe. Read More
Related
Share this page
Guest Posts by Easy Branches